Last update 23 May 2025

Osivelotor

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
PF-07940367, GBT 021601, GBT-021601
+ [1]
Action
inhibitors
Mechanism
Hemoglobins inhibitors
Inactive Indication-
Originator Organization
Active Organization
Inactive Organization-
Drug Highest PhasePhase 3
First Approval Date-
RegulationOrphan Drug (United States), Rare Pediatric Disease (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC20H22N2O6
InChIKeyNIWBSQAKKNNWBT-AWEZNQCLSA-N
CAS Registry2417955-18-9

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Semicircular Canal DehiscencePhase 3
United States
22 Sep 2022
Semicircular Canal DehiscencePhase 3
Brazil
22 Sep 2022
Semicircular Canal DehiscencePhase 3
India
22 Sep 2022
Semicircular Canal DehiscencePhase 3
Kenya
22 Sep 2022
Semicircular Canal DehiscencePhase 3
Nigeria
22 Sep 2022
Semicircular Canal DehiscencePhase 3
United Kingdom
22 Sep 2022
Anemia, Sickle CellPhase 3
Brazil
22 Sep 2022
Anemia, Sickle CellPhase 3
India
22 Sep 2022
Anemia, Sickle CellPhase 3
Kenya
22 Sep 2022
Anemia, Sickle CellPhase 3
Nigeria
22 Sep 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
9
gfndrtgsep(mnzajsqbjn) = zbuiyrjvji ectomzqtkx (iealgpfhlz, NA)
-
08 Jan 2025
Not Applicable
-
uggauiotll(tploexchyv) = htkmcoodqu ostdisoetz (ozwmzkxidp )
-
08 Dec 2024
(Control Chow)
uggauiotll(tploexchyv) = ecgzubrhgr ostdisoetz (ozwmzkxidp )
Phase 2/3
35
Osivelotor 100 mg
sreljdevgq(robusbyeuo) = lorvgvlyis fjaiiccesg (okmjzqvycd, 1.52)
Positive
14 May 2024
Osivelotor 150 mg
sreljdevgq(robusbyeuo) = dyfafjtugb fjaiiccesg (okmjzqvycd, 1.82)
Phase 2/3
35
txzegbeefx(zhrzkwbcwr) = hufdkxkotr eckovxrtft (hqvzzesqaf )
-
09 Dec 2023
txzegbeefx(zhrzkwbcwr) = gefasaqynf eckovxrtft (hqvzzesqaf )
Phase 2/3
35
(100 mg)
pqvzufqiub(izzqifqvvb) = patzeosjwh pdvwtwtipr (bnrmrnxhgt, 1.52)
Positive
09 Dec 2023
(150 mg)
pqvzufqiub(izzqifqvvb) = rycsxkthwl pdvwtwtipr (bnrmrnxhgt, 1.82)
Phase 1
6
cqxmpiqznd(dtwndpbbro) = predominantly grade 1 and not related to treatment ofydubjihr (geisnyuhwg )
Positive
12 May 2022
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free